What is preeclampsia?
Preeclampsia is a disease associated with hypertension during pregnancy that can occur from 20 weeks of gestation and that produces complications in both the mother and the fetus, such as placental abruption, premature delivery, organ failure or seizures, among others.
Preeclampsia is a serious complication in 3 to 5% of pregnancies, requiring induction of labor before the 34th week of gestation (early preeclampsia) or at the end of pregnancy (late preeclampsia).
Early detection and clear risk stratification facilitates decision making to ensure the well-being of the mother and fetus.
Symptoms:
- HYPERTENSION (systolic and diastolic) in previously normotensive women.
- PROTEINURIA: presence of protein in the urine in higher than normal concentration.
- EDEMA: fluid accumulation.
- DECREASED RENAL FUNCTION
- HEPATIC INVOLVEMENT
- HEADACHES
For which women is it indicated?
This test is indicated for all pregnant women from the 20th week of pregnancy, especially if they present some of the following risk factors:
- First pregnancy or first pregnancy with a new partner
- Preeclampsia in previous pregnancy
- Multiple pregnancy
- Pregnancy through in vitro fertilization
- Diabetes mellitus type I
- Obesity
- Women over 40 years old
- Hypertension
- Kidney problems
- Family history of cardiovascular disease
- Antiphospholipid antibody syndrome
- Lupus erythematosus
Process
Requires a simple blood sample.
Receipt and analysis of the sample in our laboratory.
Sending of the report in 3 working days.
For further clarification, your doctor will explain the results.
Results
The results of the study are essential for the physician to be able to act in time, through a diagnosis of two possible outcomes:
Diagnosis of preeclampsia | Possible risk
Diagnosis of preeclampsia: evidence of the syndrome, assessment of severity and progression; allowing rapid medical action in favor of mother and baby.
Possible risk: risk of developing preeclampsia or not in the next 4 weeks, so that the pregnant woman is kept under medical surveillance.
The Elecsys sFlt-1/PIGF ratio measurement is a reliable tool to identify those women at high risk of developing preeclampsia in the next 4 weeks and who require closer monitoring. On the other hand, it allows to detect those women with suspected preeclampsia who will not develop the disease within one week. The sFlt-1/PIGF ratio serves to differentiate preeclampsia/HELP from different forms of hypertensive disorders of pregnancy.
EARLY PREECLAMPSIA
Gestational week 20-33+6 days
| sFlt-1/PIGF > = 85 | Diagnosis | The woman has preeclampsia.
Specificity 99,5%. |
|---|---|---|
| sFlt-1/PIG < 85 > = 38 | Prediction:
Inclusion in next 4 weeks. |
High risk of developing preeclampsia in the next 4 weeks.
Positive predictive value: 38,6%. |
| sFlt-1/PIG < 38 | Prediction:
Discard in the next week. |
The woman will not develop preeclampsia in the next week.
Negative predictive value: 99,1%. |
LATE PREECLAMPSIA
Gestational week 34 to late pregnancy
| sFlt-1/PIGF > = 110 | Diagnosis | The woman has preeclampsia.
Specificity 99,5%. |
|---|---|---|
| sFlt-1/PIG < 110 > = 38 | Prediction:
Inclusion in next 4 weeks. |
High risk of developing preeclampsia in the next 4 weeks.
Positive predictive value: 38,6%. |
| sFlt-1/PIG < 38 | Prediction:
Discard in the next week. |
The woman will not develop preeclampsia in the next week.
Negative predictive value: 99,1%. |
How does it work?
Choose to take care of yourself.
Pay securely.
Go to a Cerba center.
Check your results online.
